Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 3, 2017
Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipientsDipenkumar Modi, Hyejeong Jang, Seongho Kim, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 13, 2023
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA studyShaji Kumar, Angela Dispenzieri, Divaya Bhutani, et al.
Blood Cancer Journal|January 12, 2021
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosisVikram J Premkumar, Suzanne Lentzsch, Samuel Pan, et al.
Blood|August 28, 2024
Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapyRajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, et al.
British Journal of Haematology|April 15, 2025
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world dataNoa Biran, Binod Dhakal, Ruben Niesvizky, et al.
Blood Cancer Journal|November 7, 2025
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world studySamer Al Hadidi, Aniko Szabo, Bhavesh Mohan Lal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2026
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES TrialsAshutosh D Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, et al.
Hemasphere|December 31, 2025
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab eraAbdul-Hamid Bazarbachi, Saurabh Zanwar, Ute Hegenbart, et al.
Haematologica|August 30, 2023
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myelomaLindsay Hammons, Aniko Szabo, Abhishek Janardan, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
Pageof 7